Nitin Jain, MD
Internal Medicine · Melbourne, FLNPI 1750478392
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,158 of the $11,773 with a category attached, or 69.3%. 38 manufacturers reported payments, led by Beone Medicines USA, Inc. at 32.7% of the total. 2025 is the largest year on record at $5,492, more than ten times the $374 reported in 2019. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $29.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beone Medicines USA, Inc.$4K
- AstraZeneca$1K
- AbbVie$863
- Pfizer$835
- Lilly USA, LLC$744
- Novo Nordisk$481
- plus $4K from 32 others
Across 3 payments — averaging $22,079 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$66K
What the payments were for
- Consulting fees$3,60031%
- Food & beverage$8,15869%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beone Medicines USA, Inc. | 4 | $3,850 |
| AstraZeneca | 57 | $1,058 |
| AbbVie | 43 | $863 |
| Pfizer | 44 | $835 |
| Lilly USA, LLC | 47 | $744 |
| Novo Nordisk | 26 | $481 |
| Johnson & Johnson | 12 | $471 |
| Boehringer Ingelheim | 24 | $431 |
| Exact Sciences | 14 | $337 |
| Bayer | 15 | $325 |
| Amgen | 18 | $317 |
| Esperion Therapeutics, Inc. | 10 | $212 |
| Abbott | 4 | $203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $181 |
| GSK | 9 | $170 |
| Novartis | 8 | $135 |
| Boston Scientific | 2 | $135 |
| Paratek Pharmaceuticals, Inc. | 5 | $89 |
| Merck | 5 | $87 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Kowa Pharmaceuticals America, Inc. | 5 | $82 |
| Amarin Pharma, Inc. | 5 | $81 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| Insmed, Inc. | 3 | $62 |
| Eisai Inc. | 3 | $58 |
| Astellas Pharma US Inc | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 1 | $43 |
| Dexcom, Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Bausch Health US, LLC | 2 | $33 |
| Seqirus USA Inc | 1 | $31 |
| Medtronic | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $21 |
| Radius Health, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$3,850
- XARELTO$241
- MitraClip System$145
- WATCHMAN FLX$112
How this compares
$11,773 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $122,967 |
| EliquisApixaban | 98 | $114,412 |
| JardianceEmpagliflozin | 50 | $52,988 |
| TradjentaLinagliptin | 51 | $45,758 |
| MounjaroTirzepatide | 41 | $39,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $35,406 |
| EntrestoSacubitril/Valsartan | 28 | $30,496 |
| XareltoRivaroxaban | 31 | $25,645 |
| JanuviaSitagliptin Phosphate | 18 | $24,276 |
| FarxigaDapagliflozin Propanediol | 15 | $20,697 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,417 |
| TrulancePlecanatide | 12 | $6,716 |
| Praluent PenAlirocumab | 14 | $6,512 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $6,093 |
| Rosuvastatin Calcium | 304 | $5,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $481 | $122,967115 claims |
| PfizerEliquis | $835 | $114,41298 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $431 | $104,839112 claims |
| Lilly USA, LLCMounjaro | $744 | $39,39041 claims |
| GSKTrelegy Ellipta | $170 | $35,40648 claims |
| NovartisEntresto | $135 | $30,49628 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,058 | $29,11428 claims |
| Johnson & JohnsonXarelto | $471 | $25,64531 claims |
| MerckJanuvia | $87 | $24,27618 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $181 | $6,71612 claims |
| Esperion Therapeutics, Inc.Nexletol | $212 | $5,02113 claims |
| AbbVieSynthroid | $863 | $3,08554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Melbourne
- Ronald CathcartMelbourne$150K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.